**8. Conclusion**

Ivermectin has been administered to millions of patients as an anti-parasitic drug exhibiting a wide margin of clinical safety. There exists a large body of *in vitro* and *in vivo* evidence demonstrating ivermectin's anti-tumor potential, and ivermectin's anti-tumor efficacy can be demonstrated at concentrations that are clinically attainable based on clinical pharmacokinetics. We thus propose that ivermectin be considered urgently for clinical trials either as a single agent or in combination with existing antineoplastics for cancer.
